Prostate Cancer Therapeutics Market Insights
Prostate cancer is caused by the uncontrolled growth of the cells in the prostate gland. Prostate cancer is the most common cancer in men in the U.S., after skin cancer. According to the American Community Survey, 2016, in U.S. prostate cancer is the second leading cause of death among the cancer deaths in men. Almost all prostate cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Other types of prostate cancer are rare; these include: Sarcomas, small cell carcinomas, neuroendocrine tumors and transitional cell carcinomas. Advanced stage of prostate cancer can cause men to urinate more often or have a weaker flow of urine, but these symptoms can also be caused by benign prostate conditions. In 2017, the American Cancer Society estimated around 161,360 new diagnoses of prostate cancer in the U.S., leading to around 26,730 fatalities. As the cause of the cancer is not known, there is no definite way to prevent prostate cancer. The American Cancer Society (ACS) and the National Comprehensive Cancer Network (NCCN) recommends that all men over age 40 should have an annual rectal examination and that men have an annual prostate-specific antigen (PSA) test beginning at age of 50 years.
Rising implications associated with prostate cancer are expected to affect the prostate cancer therapeutics market
Prostate cancer incidence is strongly related to age, with the highest incidence rates being in older men. According to National Cancer Registry Ireland, 2011, median age at prostate cancer diagnosis in Ireland was 67 years with 38.9% of cases being diagnosed in men and 21.3% in men 75+ years. Median age at death was 80 with 70.3% of deaths occurring in men 75+ years. Moreover, Supportive initiatives undertaken by key players in collaboration with various governments to create more awareness of clinical symptoms about prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection are also the factors which expected to boost the prostate cancer therapeutics market. However, high cost associated with drugs, and poor reimbursement of treatment cost may affect the prostate cancer therapeutics negatively.
The global prostate cancer therapeutics market was valued at US$ 8,191.11 million in 2016 and is expected to witness a CAGR of 7.5% during the forecast period (2017 – 2025).
Table 1. Prostate Cancer Drugs in Pipeline
| Drug/ Candidate |
Phases |
| Metformin |
Phase 2 |
| Avelumab |
Phase 2 |
| LY2452473 |
Phase 2 |
| Indocyanine Green (ICG) |
Phase 1 |
| Leuprolide Acetate, Prednisone, Docetaxel and Apalutamide |
Phase 2 |
Source: Clinical Trials.gov
Endeavor to introduce highly effective therapies for prostate cancer would support the market growth
Many research organizations and universities are investing in research for the development of therapeutic products for the treatment of such tumors. For instance, some pipeline products which are in phase 2 studies, such as Avelumab (Duke University Medical Center), Metformin (Mansoura University), LY2452473 (Dana-Farber Cancer Institute) are expected to arrive in the market in the near future. Furthermore, many products that are about to face patent expiry during the forecast period will also contribute in the growth of the generic prostate cancer therapeutics market. Many pharmaceutical companies are also focusing on introducing their respective drugs in different countries to boost the sales of their products. For instance, in December, 2016, Sanofi’s prostate cancer drug name Jevtana (cabazitaxel) for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) was approved by Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland, due to which Scotland has now collaborated with health authorities in Northern Ireland, England and Wales. Thereby, reducing potential disparities in care across the UK for this vulnerable group of patients.
Key players operating in the prostate cancer therapeutics market include Johnson & Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc, Endo Pharmaceuticals, AbbVie, Inc.
Prostate cancer is the most common cancer among the geriatric male population. It is a major health concern, especially in developed countries with a greater proportion of elderly men being affected by it. According to European Association of Urology, 2016, the incidence is highest in Northern and Western Europe (> 200 per 100,000 men with age group > 70 years of age), while rates in Eastern and Southern Europe have showed a continuous increase. Thus, the introduction of innovative drugs for patients with prostate cancer is required to meet the unmet needs with satisfactory results. Currently, metastatic castration-resistant prostate cancer (CRPC) is usually treated with chemotherapy (docetaxel, and cabazitaxel) or secondary hormonal therapeutic agents such as abiraterone or Triptorelin. Immunotherapy with Sipuleucel-T is prescribed in treating asymptomatic or minimally metastatic CRPC without visceral metastasis.
Market Dynamics
The market is gaining significant traction due to continuous investment by research organizations and universities for the development of therapeutic products for the treatment of such tumors. Novel therapies are expected to be predominately approved in castration-resistant patients, and to compete with better-established treatments, such as Zytiga, Xtandi and generic docetaxel, or to act as adjuvants to established therapies. For instance, there is a strong pipeline of products such as Metformin (Mansoura University), Avelumab (Duke University Medical Center), LY2452473 (Dana-Farber Cancer Institute), which are in their phase 2 studies and are projected to enter the market in the near future. However, high cost and side effects associated with drugs can restraint the market growth.
Key features of the study:
- This report provides in-depth analysis of the prostate cancer therapeutics market and its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2017 – 2025, considering 2016 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global prostate cancer therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
- Key companies covered as a part of this study include Johnson & Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc, Endo Pharmaceuticals, AbbVie, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion and marketing tactics.
- The global prostate cancer therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for prostate cancer therapeutics market, research and consulting firms, new entrants and financial analysts
- Various strategy matrices used in analyzing the prostate cancer therapeutics market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
- Global Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Global Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Prostate Cancer Therapeutics Market, By Geography:
- North America
- U.S.
- U.S. Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- U.S. Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Canada
- Canada Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Canada Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- U.K.
- U.K. Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- U.K. Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Germany
- Germany Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Germany Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Italy
- Italy Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Italy Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- France
- France Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- France Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Spain
- Spain Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Spain Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Russia
- Russia Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Russia Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Europe
- Rest of Europe Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Rest of Europe Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia-Pacific
- China
- China Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- India
- India Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- India Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Japan
- Japan Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Japan Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- ASEAN
- ASEAN Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- ASEAN Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Australia
- Australia Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Australia Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- South Korea
- South Korea Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- South Korea Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Asia Pacific
- Rest of Asia Pacific Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Rest of Asia Pacific Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- Brazil
- Brazil Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Brazil Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Mexico
- Mexico Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Mexico Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Latin America
- Rest of Latin America Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Rest of Latin America Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- GCC
- GCC Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- GCC Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Israel
- Israel Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Israel Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Middle East
- Rest of Middle East Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Rest of Middle East Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- North Africa
- North Africa Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- North Africa Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Central Africa
- Central Africa Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- Central Africa Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- South Africa
- South Africa Prostate Cancer Therapeutics Market, By Drug Type:
- Hormonal Therapy
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonist
- Abiraterone Acetate (Zytiga)
- Degarelix Acetate (Firmagon/Gonax)
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Goserelin Acetate (Zoladex)
- Leuprorelin acetate (Prostap or Lutrate)
- Triptorelin (Trelstar)
- Others
- Anti-Androgens
- Enzalutamide (Xtandi)
- Nilutamide (Nilandron)
- Others
- Immunotherapy
- Targeted Therapy
- Radium 223 Dichloride (Xofigo)
- Chemotherapy
- Cabazitaxel (Jevtana)
- Docetaxel (Taxotere)
- South Africa Prostate Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Future Plans
- Astellas Pharma Inc.
- AstraZeneca Plc
- Sanofi
- Bayer AG
- Pfizer, Inc.
- Dendreon Corporation (Sanpower Group Co. Ltd.)
- Ipsen Group
- Tolmar Inc.
- Endo International plc
- AbbVie, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
